Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A. Mittendorf, Nadia Harbeck, Andreas Koehler et al.|The Lancet|2020Cited by 1.1k
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramFátima Cardoso, Sharon H. Giordano, John M.S. Bartlett et al.|Annals of Oncology|2017Cited by 396
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al.|Annals of Oncology|2021Cited by 294